Hospital

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

PCOS in female athletes often goes unrecognized due to atypical presentations, requiring careful differentiation, individualized management, and a multidisciplinary approach to protect both performance and long-term health.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

LIV Process is a patented, water-based solution that allows hospitals and long-term care facilities to see live C difficile spores on surfaces in 2 minutes.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

Team-based hypertension care puts pharmacists and home blood pressure monitoring at the front line, boosting control rates and saving lives and costs.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.

LTOT opioid therapy declines, but gabapentinoid coprescribing rises—impact on chronic pain management, safety, and prescriptions.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Kyle Fischer, PharmD, explains navigating payer hurdles, supporting adherence, and improving coordination in ILD and PAH care.

A unified specialty pharmacy platform replaces fragmented tools, streamlines access, boosts reimbursement clarity, and supports advanced therapies.

Clinical pharmacists are uniquely positioned to deliver a continuation appropriateness measure that no existing quality framework produces.

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and FDA approval of a higher-dose regimen for spinal muscular atrophy.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Air pollution exposure, particularly fine particulate matter and ozone, may worsen cardiac outcomes in patients with breast cancer receiving cardiotoxic therapies.

Pharmacist Kyle Fischer, PharmD, APh, explains how antifibrotic therapy, drug interactions, and pharmacist–physician collaboration guide ILD care.

Waters Corporation's Onclarity HPV Self-Collection Kit represents a significant advance in expanding access to cervical cancer screening outside the clinic.

The CDC testing pause disrupts diagnostic testing for infectious diseases like rabies and mpox, leaving pharmacists and states scrambling for answers.

Meitheal Pharmaceuticals launches propofol sedation vials for ICU and surgery, cutting waste and dosing errors with 3 single-dose sizes.

Practical strategies to improve clozapine education, monitoring, and utilization while addressing common barriers and safety concerns.

Phase 3 PATCH trial data show estrogen patches reduce hot flashes but raise gynecomastia risk.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.